<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Orphan drug</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Pediatric PRVs top the voucher popularity contest</title>
      <description>
        <![CDATA[With three rare pediatric disease priority review vouchers (RPD PRVs) awarded just since the end of March, the nearly year-and-a-half lapse in the program’s reauthorization seems to have had little short-term impact. The three new vouchers bring the total RPD PRVs granted so far this year to seven – one more than the agency issued all last year and down two from the nine given in 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730209</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730209-pediatric-prvs-top-the-voucher-popularity-contest</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/Pediatric-exam3.webp?t=1758231919" type="image/jpeg" medium="image" fileSize="423899">
        <media:title type="plain">Pediatric exam</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK’s IBAT inhibitor wins US FDA nod for cholestatic pruritus </title>
      <description>
        <![CDATA[With the U.S. FDA’s approval of GSK plc’s ileal bile acid transporter (IBAT) inhibitor, Lynavoy (linerixibat), patients with primary biliary cholangitis no longer need off-label treatments for a debilitating internal itch symptom called cholestatic pruritus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729745</guid>
      <pubDate>Thu, 19 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729745-gsks-ibat-inhibitor-wins-us-fda-nod-for-cholestatic-pruritus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Wood-approved-stamp-red.webp?t=1670969940" type="image/png" medium="image" fileSize="323015">
        <media:title type="plain">Red wooden approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Otsuka’s repinatrabit shows phase II efficacy in PKU adolescents</title>
      <description>
        <![CDATA[Otsuka Pharmaceutical Co. Ltd. reaped positive results from an open-label phase II study of repinatrabit (JNT-517) in adolescents with phenylketonuria (PKU), a rare disease marked by the inability to break down the amino acid phenylalanine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729717</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729717-otsukas-repinatrabit-shows-phase-ii-efficacy-in-pku-adolescents</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Molecule-illustration.webp?t=1599684844" type="image/png" medium="image" fileSize="508796">
        <media:title type="plain">Molecule illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Otsuka’s repinatrabit shows phase II efficacy in PKU adolescents</title>
      <description>
        <![CDATA[Otsuka Pharmaceutical Co. Ltd. reaped positive results from an open-label phase II study of repinatrabit (JNT-517) in adolescents with phenylketonuria (PKU), a rare disease marked by the inability to break down the amino acid phenylalanine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729496</guid>
      <pubDate>Fri, 13 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729496-otsukas-repinatrabit-shows-phase-ii-efficacy-in-pku-adolescents</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Molecule-illustration.webp?t=1599684844" type="image/png" medium="image" fileSize="508796">
        <media:title type="plain">Molecule illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA’s rare disease toolbox not fully used</title>
      <description>
        <![CDATA[At the current pace of innovation in the U.S. rare disease space, developing and approving therapies for just half of the 10,000-plus known rare diseases would take more than 160 years, Bradley Campbell, president and CEO of Amicus Therapeutics Inc., recently told the Senate Committee on Aging.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729300</guid>
      <pubDate>Wed, 04 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729300-fdas-rare-disease-toolbox-not-fully-used</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Magnifying-glass-clock-and-capsules.webp?t=1772663070" type="image/jpeg" medium="image" fileSize="570788">
        <media:title type="plain">Magnifying glass, clock and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Experts: Regulatory roadblocks stalling rare disease therapies</title>
      <description>
        <![CDATA[A lot of distance lies between talking regulatory flexibility and actually being flexible. That message was driven home again after Uniqure NV disclosed in its latest earnings report March 2 that the U.S. FDA wants a sham-controlled study before it will consider approval of the company’s gene therapy AMT-130 in Huntington’s, a rare disease currently affecting about 41,000 people in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729285</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729285-experts-regulatory-roadblocks-stalling-rare-disease-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Red-and-white-roadblock.webp?t=1772577246" type="image/jpeg" medium="image" fileSize="267899">
        <media:title type="plain">Red and white roadblock</media:title>
      </media:content>
    </item>
    <item>
      <title>Tessera’s TSRA-196 designated orphan drug for AATD</title>
      <description>
        <![CDATA[Tessera Therapeutics Inc.’s lead in vivo gene editing program, TSRA-196, has been awarded orphan drug and fast track designations by the FDA for adults with α-1 antitrypsin deficiency (AATD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729019</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729019-tesseras-tsra-196-designated-orphan-drug-for-aatd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-edit-genomics.webp?t=1747837759" type="image/jpeg" medium="image" fileSize="1061729">
        <media:title type="plain">DNA double helix under a magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Affinia’s AFTX-201 designated EU orphan drug </title>
      <description>
        <![CDATA[Affinia Therapeutics Inc.’s AFTX-201 has been awarded orphan drug designation by the EMA for BAG3-associated dilated cardiomyopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728941</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728941-affinias-aftx-201-designated-eu-orphan-drug</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>US CMS names its choices for third round of price negotiations</title>
      <description>
        <![CDATA[The pressure on U.S. drug prices continues, with the CMS lining up the drugs for round 3 of negotiations, which will set maximum fair prices to go into effect in 2028. The slate includes 15 drugs and, for the first time, opens the negotiations to Part B drugs, as well as Part D. Consequently, seven of the 15 selected drugs are biologics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728341</guid>
      <pubDate>Wed, 28 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728341-us-cms-names-its-choices-for-third-round-of-price-negotiations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-capsule-and-dollar-sign.webp?t=1617651432" type="image/png" medium="image" fileSize="186891">
        <media:title type="plain">Drug capsule and dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Adolore’s CA8* gene therapy designated orphan drug</title>
      <description>
        <![CDATA[Adolore Biotherapeutics Inc. has announced that the FDA has granted orphan drug designation to the company’s Kv7-activating rdHSV-CA8* gene therapy for treatment of primary and secondary erythromelalgia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728034</guid>
      <pubDate>Fri, 16 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728034-adolores-ca8-gene-therapy-designated-orphan-drug</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-editing.webp?t=1730128296" type="image/jpeg" medium="image" fileSize="222415">
        <media:title type="plain">DNA double helix illustration with section being removed in red</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears Askbio’s IND for AB-1009 for late-onset Pompe disease</title>
      <description>
        <![CDATA[Askbio Inc., a subsidiary of Bayer AG, has received IND clearance from the FDA for AB-1009, an AAV gene therapy being developed for the treatment of late-onset Pompe disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727855</guid>
      <pubDate>Fri, 09 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727855-fda-clears-askbios-ind-for-ab-1009-for-late-onset-pompe-disease</link>
    </item>
    <item>
      <title>Arbele’s ARB-1002 designated orphan drug for pancreatic cancer</title>
      <description>
        <![CDATA[Arbele Pte Ltd.’s ARB-1002 has been awarded orphan drug designation by the FDA for the treatment of pancreatic cancer. ARB-1002 is an antibody-drug conjugate comprising an anti-CDH17 monoclonal antibody chemically linked to a potent cytotoxic agent.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727744</guid>
      <pubDate>Thu, 08 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727744-arbeles-arb-1002-designated-orphan-drug-for-pancreatic-cancer</link>
    </item>
    <item>
      <title>Immusoft’s ISP-002 designated US orphan drug for MPS II</title>
      <description>
        <![CDATA[Immusoft of CA Inc., a wholly owned subsidiary of Immusoft Corp., has announced that the FDA has granted orphan drug designation to ISP-002, the company’s investigational engineered B-cell therapy for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727154</guid>
      <pubDate>Tue, 16 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727154-immusofts-isp-002-designated-us-orphan-drug-for-mps-ii</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Genetic-mutation-illustration.webp?t=1759498851" type="image/png" medium="image" fileSize="448572">
        <media:title type="plain">Missing puzzle piece and broken DNA chain</media:title>
      </media:content>
    </item>
    <item>
      <title>EU agrees to pharma legislation, but the industry isn’t happy</title>
      <description>
        <![CDATA[The EU finally reached agreement on an update of the 20-year-old pharmaceutical legislation, more than five years after the EU Commission first put forward the case for reform and following two and a half years of negotiations on the new rules.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726988</guid>
      <pubDate>Mon, 15 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726988-eu-agrees-to-pharma-legislation-but-the-industry-isnt-happy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Europe-pills-syringe-flag.webp?t=1588624886" type="image/png" medium="image" fileSize="617433">
        <media:title type="plain">EU flag, pills, syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Vigencell’s cell therapy for lymphoma meets phase II endpoint  </title>
      <description>
        <![CDATA[Vigencell Inc. plans to seek conditional approval in South Korea for VT-EBV-N, an antigen-specific killer T-cell therapy for natural killer T-cell lymphoma, after gaining positive top-line data from a phase II study Nov. 25.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726794</guid>
      <pubDate>Tue, 02 Dec 2025 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726794-vigencells-cell-therapy-for-lymphoma-meets-phase-ii-endpoint</link>
    </item>
    <item>
      <title>Kedrion’s aceruloplasminemia treatment designated EU orphan drug</title>
      <description>
        <![CDATA[Kedrion SpA’s investigational plasma-derived treatment for congenital aceruloplasminemia has been awarded European orphan drug designation by the EMA. The company is working to advance this treatment toward clinical development in Europe.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726650</guid>
      <pubDate>Fri, 28 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726650-kedrions-aceruloplasminemia-treatment-designated-eu-orphan-drug</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Plasma-bags.webp?t=1598302099" type="image/png" medium="image" fileSize="470351">
        <media:title type="plain">Bags of plasma</media:title>
      </media:content>
    </item>
    <item>
      <title>Vigencell’s cell therapy for lymphoma meets phase II endpoint  </title>
      <description>
        <![CDATA[Vigencell Inc. plans to seek conditional approval in South Korea for VT-EBV-N, an antigen-specific killer T-cell therapy for natural killer T-cell lymphoma, after gaining positive top-line data from a phase II study Nov. 25.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726510</guid>
      <pubDate>Wed, 26 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726510-vigencells-cell-therapy-for-lymphoma-meets-phase-ii-endpoint</link>
    </item>
    <item>
      <title>Leukogene’s LTI-214 designated orphan drug for AML</title>
      <description>
        <![CDATA[Leukogene Therapeutics Inc.’s lead product candidate LTI-214 (M2T-CD33) has been awarded orphan drug designation by the FDA for the treatment of acute myeloid leukemia (AML).]]>
      </description>
      <guid>http://www.bioworld.com/articles/725834</guid>
      <pubDate>Wed, 05 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725834-leukogenes-lti-214-designated-orphan-drug-for-aml</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-immunotherapy.webp?t=1652309698" type="image/png" medium="image" fileSize="423060">
        <media:title type="plain">Cancer cells being destroyed by immunotherapy</media:title>
      </media:content>
    </item>
    <item>
      <title>Dewpoint’s condensate modulator wins FDA orphan drug status</title>
      <description>
        <![CDATA[The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint’s IND application for DPTX-3186 earlier in October, and is the first orphan designation ever granted to a condensate-modulating therapeutic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725713</guid>
      <pubDate>Thu, 30 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725713-dewpoints-condensate-modulator-wins-fda-orphan-drug-status</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/gastrointestinal-stomach-highlight-illustration.webp?t=1761847298" type="image/jpeg" medium="image" fileSize="709895">
        <media:title type="plain">Illustration of organs in the torso with the stomach highlighted</media:title>
      </media:content>
    </item>
    <item>
      <title>Exousia’s candidate for malignant glioma gains US orphan drug status</title>
      <description>
        <![CDATA[Exousia Pro Inc.’s subsidiary, Exousia AI, has received orphan drug designation from the FDA for its exosome-based treatment for malignant glioma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725657</guid>
      <pubDate>Wed, 29 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725657-exousias-candidate-for-malignant-glioma-gains-us-orphan-drug-status</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/3D-head-brain-cancer.webp?t=1588879177" type="image/png" medium="image" fileSize="203697">
        <media:title type="plain">Brain cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Resolute’s RS-5 designated orphan drug for soft tissue sarcomas</title>
      <description>
        <![CDATA[Resolute Science Inc.’s RS-5 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcomas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725608</guid>
      <pubDate>Mon, 27 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725608-resolutes-rs-5-designated-orphan-drug-for-soft-tissue-sarcomas</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Fibrosarcoma-soft-tissue-sarcoma.webp?t=1732551251" type="image/jpeg" medium="image" fileSize="1812959">
        <media:title type="plain">Light micrograph of fibrosarcoma, a type of soft tissue sarcoma</media:title>
      </media:content>
    </item>
    <item>
      <title>Revir’s RTX-117 designated orphan drug for Charcot-Marie-Tooth disease</title>
      <description>
        <![CDATA[Revir Therapeutics Inc.’s RTX-117 has been awarded orphan drug designation by the FDA for Charcot-Marie-Tooth disease. RTX-117 is a small-molecule therapy designed to activate eIF2B to restore translation of cap-dependent mRNAs to normalize protein expression.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725107</guid>
      <pubDate>Tue, 14 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725107-revirs-rtx-117-designated-orphan-drug-for-charcot-marie-tooth-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Motor-neuron-muscle.webp?t=1675957121" type="image/png" medium="image" fileSize="1756485">
        <media:title type="plain">Illustration of motor neuron connecting to muscle fiber</media:title>
      </media:content>
    </item>
    <item>
      <title>FOXG1 Research Foundation’s FRF-001 designated orphan drug</title>
      <description>
        <![CDATA[The FDA has granted orphan drug designation to FRF-001, the FOXG1 Research Foundation’s lead gene therapy candidate for the treatment of FOXG1 syndrome. This follows the FDA’s earlier award of rare pediatric disease designation to the investigational therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724677</guid>
      <pubDate>Wed, 01 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724677-foxg1-research-foundations-frf-001-designated-orphan-drug</link>
    </item>
    <item>
      <title>FDA continues to build regenerative medicine pathway </title>
      <description>
        <![CDATA[The U.S. FDA released a trio of draft guidances to help sponsors in developing and monitoring cell and gene therapies, as well as other regenerative medicine therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724550</guid>
      <pubDate>Fri, 26 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724550-fda-continues-to-build-regenerative-medicine-pathway</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-therapy-illustration.webp?t=1608150701" type="image/png" medium="image" fileSize="436394">
        <media:title type="plain">DNA in drug capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Cure Rare Disease’s CRD-003 designated orphan drug for LGMD2i/R9</title>
      <description>
        <![CDATA[The FDA has awarded orphan drug designation to Cure Rare Disease’s CRD-003 for the treatment of limb-girdle muscular dystrophy type R9 (LGMD2i/R9), a congenital muscular dystrophy caused by biallelic mutations in the FKRP gene.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724511</guid>
      <pubDate>Thu, 25 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724511-cure-rare-diseases-crd-003-designated-orphan-drug-for-lgmd2i-r9</link>
    </item>
    <item>
      <title>Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab </title>
      <description>
        <![CDATA[A failed July inspection of manufacturer Catalent Indiana LLC has delayed another U.S. FDA approval, the latest being that of Scholar Rock Inc.’s selective anti-latent myostatin antibody, apitegromab, which was expected to become the first therapy to enhance skeletal muscle in patients with spinal muscular atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724386</guid>
      <pubDate>Tue, 23 Sep 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724386-another-catalent-indiana-delay-scholar-rock-gets-crl-for-apitegromab</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Delayed-stamp.webp?t=1679431624" type="image/png" medium="image" fileSize="358911">
        <media:title type="plain">Delayed stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>NS Pharma’s NS-051 designated orphan drug for DMD</title>
      <description>
        <![CDATA[NS Pharma Inc.’s NS-051 (NCNP-04) has been awarded orphan drug designation by the FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/724415</guid>
      <pubDate>Mon, 22 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724415-ns-pharmas-ns-051-designated-orphan-drug-for-dmd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Pediatric-limb-exam.webp?t=1694037136" type="image/jpeg" medium="image" fileSize="194761">
        <media:title type="plain">Doctor examining child's leg</media:title>
      </media:content>
    </item>
    <item>
      <title>Capsida's gene therapy trial paused upon first patient's death</title>
      <description>
        <![CDATA[Two months after starting the phase I/II Synrgy trial with its gene therapy, CAP-002, enrolling 12 pediatric patients with rare disease STXBP1 encephalopathy, Capsida Biotherapeutics paused the study following the death of the trial’s first patient.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724060</guid>
      <pubDate>Thu, 11 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724060-capsidas-gene-therapy-trial-paused-upon-first-patients-death</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA.webp?t=1616096016" type="image/png" medium="image" fileSize="453052">
        <media:title type="plain">Brain and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Neuronos’ BA-101 designated orphan drug for glioblastoma</title>
      <description>
        <![CDATA[Neuronos Ltd., a subsidiary of Beyond Air Inc., has announced the granting of orphan drug designation by the FDA to BA-101 for the treatment of glioblastoma (GBM). The company is advancing development of BA-101 toward first-in-human studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723980</guid>
      <pubDate>Tue, 09 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723980-neuronos-ba-101-designated-orphan-drug-for-glioblastoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/glioblastoma-multiforme-GBM.webp?t=1754574743" type="image/jpeg" medium="image" fileSize="432721">
        <media:title type="plain">Microscopic image showing histology of a glioblastoma multiforme</media:title>
        <media:description type="plain">Microscopic image showing histology of a glioblastoma multiforme.</media:description>
      </media:content>
    </item>
    <item>
      <title>OBBBA changes odds for next round of US Rx price negotiations</title>
      <description>
        <![CDATA[Oddsmakers placing their bets on which drugs will be in play for round 3 of the U.S. Inflation Reduction Act (IRA) price negotiations are doing some reshuffling, thanks to an orphan drug provision tucked into the Trump administration’s One Big Beautiful Bill Act (OBBBA) that was signed into law on the Fourth of July.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723802</guid>
      <pubDate>Wed, 03 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723802-obbba-changes-odds-for-next-round-of-us-rx-price-negotiations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Prescription-drug-bottles-and-pills.webp?t=1623264455" type="image/png" medium="image" fileSize="297425">
        <media:title type="plain">Prescription drug bottles and pills</media:title>
      </media:content>
    </item>
  </channel>
</rss>
